Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells

Iwamoto, Yoichi; Ishii, Kenichiro; Kanda, Hideki; Kato, Manabu; Miki, Manabu; Kajiwara, Shinya; Arima, Kiminobu; Shiraishi, Taizo; Sugimura, Yoshiki

doi:10.1007/s00432-017-2367-9

Cited by 17 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combining RT with other therapeutic approaches has drawn great attention in the past few years, which significantly enhanced anticancer efficacy and decreased systemic toxicity. 104,105 In 2016, Liu et al 66 reported the successful synthesis of novel NMOFs that were used for the combination of PDT and RT in a murine breast cancer model. In this NMOFs platform, TCPP served as a PS of PDT, and Hf 4+ with strong X-ray attenuation ability functioned as a radiosensitizer to enhance RT-induced tumor killing.…”

Section: Pdt/rtmentioning

confidence: 99%

<p>Recent Progress of Nanoscale Metal-Organic Frameworks in Cancer Theranostics and the Challenges of Their Clinical Application</p>

Sun¹,

Li²,

Tang³

et al. 2020

IJN

View full text Add to dashboard Cite

The growing incidence of cancer raises an urgent need to develop effective diagnostic and therapeutic strategies. With the rapid development of nanomedicine, nanoscale metal-organic frameworks (NMOFs) presented promising potential in various biomedical applications in the last 2 decades, especially in cancer theranostics. Due to the unique features of NMOFs, including structural diversities, enormous porosity, multifunctionality and biocompatibility, they have been widely used to deliver imaging contrast agents and therapeutic drugs. Moreover, multiple types of contrast agents, anti-cancer drugs and targeting ligands could be co-delivered through one single NMOF to enable combination therapy. Co-delivering system using NMOFs helped to avoid multidrug resistance, to reduce adverse effects, to achieve imaging-guided precise therapy and to enhance anti-cancer efficacy. This review summarized the recent research advances on the application of NMOFs in biomedical imaging and cancer treatments in the last few years. The current challenges that impeding their translation to clinical practices and the perspectives for their future applications were also highlighted and discussed.

show abstract

Section: Pdt/rtmentioning

confidence: 99%

<p>Recent Progress of Nanoscale Metal-Organic Frameworks in Cancer Theranostics and the Challenges of Their Clinical Application</p>

Sun¹,

Li²,

Tang³

et al. 2020

IJN

View full text Add to dashboard Cite

show abstract

“…Hence, these success stories have become prominent and still practicing in the context of drug repositioning. Recent knowledge-based DR studies on PCa have presented new candidates such as ormeloxifene ( Hafeez et al, 2017 ), naftopidil ( Iwamoto et al, 2017 ), ferroquine (FQ) ( Kondratskyi et al, 2017 ), nelfinavir ( Guan et al, 2015 ), nitroxoline ( Chang et al, 2015 ), and glipizide ( Qi et al, 2016 ).…”

Section: Drug Repositioning Approaches For the Treatment Of Pcamentioning

confidence: 99%

“…The selective adrenoreceptor A1D antagonist naftopidil is used for treating lower urinary tract symptoms triggered by benign prostatic hyperplasia ( Masumori, 2011 ). Iwamoto et al (2017) proposed naftopidil therapy in combination with RT to increase treatment efficiency. They reported significant growth inhibitory effects in addition to Akt phosphorylation-inhibitory effects of naftopidil.…”

Section: Drug Repositioning Approaches For the Treatment Of Pcamentioning

confidence: 99%

Drug Repositioning for Effective Prostate Cancer Treatment

et al. 2018

View full text Add to dashboard Cite

Drug repositioning has gained attention from both academia and pharmaceutical companies as an auxiliary process to conventional drug discovery. Chemotherapeutic agents have notorious adverse effects that drastically reduce the life quality of cancer patients so drug repositioning is a promising strategy to identify non-cancer drugs which have anti-cancer activity as well as tolerable adverse effects for human health. There are various strategies for discovery and validation of repurposed drugs. In this review, 25 repurposed drug candidates are presented as result of different strategies, 15 of which are already under clinical investigation for treatment of prostate cancer (PCa). To date, zoledronic acid is the only repurposed, clinically used, and approved non-cancer drug for PCa. Anti-cancer activities of existing drugs presented in this review cover diverse and also known mechanisms such as inhibition of mTOR and VEGFR2 signaling, inhibition of PI3K/Akt signaling, COX and selective COX-2 inhibition, NF-κB inhibition, Wnt/β-Catenin pathway inhibition, DNMT1 inhibition, and GSK-3β inhibition. In addition to monotherapy option, combination therapy with current anti-cancer drugs may also increase drug efficacy and reduce adverse effects. Thus, drug repositioning may become a key approach for drug discovery in terms of time- and cost-efficiency comparing to conventional drug discovery and development process.

show abstract

“…Whereupon, Naftopidil was described to induce apoptosis in vitro in mesothelioma 30 and to inhibit growth of several cancer cells in vitro and in vivo [31][32][33] . Moreover, it efficiently sensitized PC-3 xenograft cells to radiation and docetaxel-induced apoptosis 34,35 . Study of molecular mechanisms involved in apoptosis events highlighted that its action could be independent of α 1 -AR blocking 30,36 and it was reported that Naftopidil bound directly to tubulin and inhibited its polymerization 37 .…”

Section: Introductionmentioning

confidence: 99%

Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib

et al. 2020

View full text Add to dashboard Cite

Ovarian cancer represents the first cause of mortality from gynecologic malignancies due to frequent chemoresistance occurrence. Increasing the [BH3-only Bim, Puma, Noxa proapoptotic]/[Bcl-x L , Mcl-1 antiapoptotic] proteins ratio was proven to efficiently kill ovarian carcinoma cells and development of new molecules to imbalance Bcl-2 member equilibrium are strongly required. Drug repurposing constitutes an innovative approach to rapidly develop therapeutic strategies through exploitation of established drugs already approved for the treatment of noncancerous diseases. This strategy allowed a renewed interest for Naftopidil, an α 1-adrenergic receptor antagonist commercialized in Japan for benign prostatic hyperplasia. Naftopidil was reported to decrease the incidence of prostate cancer and its derivative was described to increase BH3-only protein expression in some cancer models. Based on these arguments, we evaluated the effects of Naftopidil on ovarian carcinoma and showed that Naftopidil reduced cell growth and increased the expression of the BH3-only proteins Bim, Puma and Noxa. This effect was independent of α 1-adrenergic receptors blocking and involved ATF4 or JNK pathway depending on cellular context. Finally, Naftopidil-induced BH3only members sensitized our models to ABT-737 and Trametinib treatments, in vitro as well as ex vivo, in patientderived organoid models.

show abstract

Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells

Abstract: These results suggest that additive naftopidil treatment in combination with RT may increase the efficacy of RT for the treatment of PCa.

Cited by 17 publications

References 27 publications

<p>Recent Progress of Nanoscale Metal-Organic Frameworks in Cancer Theranostics and the Challenges of Their Clinical Application</p>

<p>Recent Progress of Nanoscale Metal-Organic Frameworks in Cancer Theranostics and the Challenges of Their Clinical Application</p>

Drug Repositioning for Effective Prostate Cancer Treatment

Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib

Contact Info

Product

Resources

About